Cochrane · systematic review · CD009444
Cholinesterase inhibitors for rarer dementias associated with neurological conditions
Li, Y, Hai, S, Zhou, Y, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
Dementia and Cognitive ImprovementAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
22
current version
GRADE rated
22
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 22.7%Moderate 10 · 45.5%High 7 · 31.8%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Cholinersterase inhibitors for Huntington's disease (short‐term)
Population: Huntington's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function ‐ the Cognitive portion of the Alzheimer Disease Assessment Scale ADAS‐Cog1 | no estimate extracted | 1 study · 24 participants | Low Downgraded: risk of bias, imprecision |
Cognitive function ‐ the Unified Huntington's Disease Rating Scale‐Symbol Digit Modalities Test change UHDRS‐SDMT1 | no estimate extracted | 1 study · 24 participants | Low Downgraded: risk of bias, imprecision |
Cognitive function ‐ the Unified Huntington's Disease Rating Scale‐Verbal Fluency Test change UHDRS‐FAS1 | no estimate extracted | 1 study · 24 participants | Low Downgraded: risk of bias, imprecision |
Cholinesterase inhibitors for Huntington's disease (medium‐term)
Population: Huntington's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function ‐ Verbal fluency test Verbal fluency test1 | no estimate extracted | 1 study · 17 participants | Moderate Downgraded: imprecision |
Cognitive function ‐Symbol Digit Modalities Test SDMT1 | no estimate extracted | 1 study · 17 participants | Moderate Downgraded: imprecision |
Cognitive function ‐ California Verbal Learning Test‐II trials 1‐5 CVLT‐II trials 1‐51 | no estimate extracted | 1 study · 17 participants | Moderate Downgraded: imprecision |
Cognitive function ‐ California Verbal Learning Test‐II short‐delay recall CVLT‐II SD recall1 | no estimate extracted | 1 study · 17 participants | Moderate Downgraded: imprecision |
Cognitive function ‐ California Verbal Learning Test‐II long‐delay recall CVLT‐II LD recall1 | no estimate extracted | 1 study · 17 participants | Moderate Downgraded: imprecision |
Cognitive function ‐ California Verbal Learning Test‐II recognition task CVLT‐II recognition task1 | no estimate extracted | 1 study · 17 participants | Moderate Downgraded: imprecision |
Cholinesterase inhibitors for multiple sclerosis (short‐term)
Population: Multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function ‐ Wechsler Memory Scales WMS‐general memory score1 | no estimate extracted | 1 study · 60 participants | Low Downgraded: risk of bias, imprecision |
Cholinesterase inhibitors for multiple sclerosis (medium‐term)
Population: Multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function ‐ Selective Reminding Test total SRT1 | no estimate extracted | 3 studies · 270 participants | High |
Clinical global impression of change ‐ patient's self‐reported impression of memory change | OR 1.67 [0.93, 3] | 2 studies · 189 participants | High |
Clinical global impression of change ‐ patient's self‐reported impression of cognitive change | OR 0.95 [0.45, 1.98] | 1 study · 120 participants | High |
Clinical global impression of change ‐ clinician's impression of memory change | OR 1.95 [0.88, 4.3] | 1 study · 120 participants | Moderate Downgraded: imprecision |
Clinical global impression of change ‐ clinician's impression of cognitive change | OR 1.96 [1.06, 3.62] | 2 studies · 189 participants | High |
Activities of daily living ‐ Patient reported impact of multiple sclerosis activities Patient reported impact of multiple sclerosis activities1 | no estimate extracted | 1 study · 81 participants | Low Downgraded: risk of bias, imprecision |
Cholinesterase inhibitors for CADASIL
Population: CADASIL
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function ‐ the Cognitive portion of the Vascular Alzheimer Disease Assessment Scale change V‐ADAS‐Cog1 | no estimate extracted | 1 study · 161 participants | High |
Clinical global impression of change ‐ the Sum of Boxes of the Clinical Dementia Rating Scale CDR‐SB1 | no estimate extracted | 1 study · 161 participants | High |
Activities of daily living ‐ Disability Assessment for Dementia scale DAD1 | no estimate extracted | 1 study · 161 participants | Moderate Downgraded: imprecision |
Adverse events associated with the use of cholinesterase inhibitors for rarer dementias
Population: Patients with neurological conditions associated with rarer dementias
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Nausea | OR 2.1 [1.22, 3.62] | 6 studies · 503 participants | High |
Diarrhea | OR 3.26 [1.72, 6.19] | 6 studies · 503 participants | Moderate Downgraded: imprecision |
Vomiting | OR 5.76 [1.67, 19.87] | 3 studies · 374 participants | Moderate Downgraded: imprecision |